The Global Implantable Drug Delivery Device Market is estimated to be USD 18.35 Bn in 2021 and is expected to reach USD 28.82 Bn by 2026, growing at a CAGR of 9.45%.
However, the chances of implanted device failures, strict government regulations and policies, and the high cost of devices are expected to restrain the market growth in the forecasted period.
By Product, the market is classified into Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bioabsorbable Stents, Intraocular Implants, Infusion Pumps, and Others. Amongst all, the Drug-Eluting Stents segment is estimated to hold the highest market share during the forecast period.
By Type, the market is classified as Bio-Degradable And Non-Biodegradable. Amongst the two, the Non-Biodegradable segment is estimated to hold the highest market share during the forecast period.
By Technology, the market is classified as Diffusion, Osmotic, and Magnetic. Amongst all, the Diffusion segment is estimated to hold the highest market share during the forecast period.
By Application, the market is classified as Ophthalmology, Cardiology, Obstetrics And Gynecology, Diabetes, Oncology, Auto-Immune Diseases, and Others. Amongst all, the Cardiovascular segment is estimated to hold the highest market share during the forecast period.
By End-User, the market is classified as Hospitals, Ambulatory Surgery Centers, and Others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
2. Siemens Healthineers acquired Varian, strengthening its position as a holistic partner in healthcare -15th April 2021
Market Dynamics
The growth of the implantable drug-device market is driven by factors such as the growing prevalence of chronic disease, the rising awareness amongst people regarding implantable drug delivery devices, increasing demand for contraceptives, and intervention by government and health organizations to ensure high patient safety standards. In addition, the rising awareness about the availability of high quality and safer products, recent advancements in medication administration techniques, and rapid increasing research and development for new product launch and elimination of existing problems are expected to fuel growth potential over the coming years.However, the chances of implanted device failures, strict government regulations and policies, and the high cost of devices are expected to restrain the market growth in the forecasted period.
Market Segmentation
The Global Implantable Drug Delivery Device Market is segmented further based on Product, Type, Technology, Application, End-User, and Geography.By Product, the market is classified into Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bioabsorbable Stents, Intraocular Implants, Infusion Pumps, and Others. Amongst all, the Drug-Eluting Stents segment is estimated to hold the highest market share during the forecast period.
By Type, the market is classified as Bio-Degradable And Non-Biodegradable. Amongst the two, the Non-Biodegradable segment is estimated to hold the highest market share during the forecast period.
By Technology, the market is classified as Diffusion, Osmotic, and Magnetic. Amongst all, the Diffusion segment is estimated to hold the highest market share during the forecast period.
By Application, the market is classified as Ophthalmology, Cardiology, Obstetrics And Gynecology, Diabetes, Oncology, Auto-Immune Diseases, and Others. Amongst all, the Cardiovascular segment is estimated to hold the highest market share during the forecast period.
By End-User, the market is classified as Hospitals, Ambulatory Surgery Centers, and Others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Recent Developments
1. FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD). If approved, PDS would be the first and only eye implant with continuous drug delivery that offers people living with nAMD an alternative to frequent eye injections - 24th June 2021.2. Siemens Healthineers acquired Varian, strengthening its position as a holistic partner in healthcare -15th April 2021
Company Profiles
Some of the companies covered in this report are Allergan, Bayer AG, Medtronic, Abbott, Varian Medical Systems Inc., etc.Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.Why buy this report?
- The report offers a comprehensive evaluation of the Global Implantable Drug Delivery Device Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
- The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Implantable Drug Delivery Device Market
What is the estimated value of the Global Implantable Drug Delivery Device Market?
What is the growth rate of the Global Implantable Drug Delivery Device Market?
What is the forecasted size of the Global Implantable Drug Delivery Device Market?
Who are the key companies in the Global Implantable Drug Delivery Device Market?
Report Attribute | Details |
---|---|
No. of Pages | 193 |
Published | June 2021 |
Forecast Period | 2021 - 2026 |
Estimated Market Value ( USD
| USD 18350 Million |
Forecasted Market Value ( USD
| USD 28820 Million |
Compound Annual Growth Rate | 9.4% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Implantable Drug Delivery Device Market, By Product
7 Global Implantable Drug Delivery Device Market, By Type
8 Global Implantable Drug Delivery Device Market, By Technology
9 Global Implantable Drug Delivery Device Market, By Application
10 Others Global Implantable Drug Delivery Device Market, By End User
11 Global Implantable Drug Delivery Device Market, By Geography
12 Competitive Landscape
13 Company Profiles
14 Appendix
Companies Mentioned
- Abbott Laboratories
- AbbVie Inc
- Allergan Inc
- Alcon Inc.
- Bayer AG
- Bausch and Lomb Incorporated
- Biotronik, Inc.
- Boston Scientific Corporation
- DSM Biomedical
- Delpor Inc.
- Medtronic Plc.
- Merck & co., Inc.
- Freudenberg Medical, LLC
- Flowonix
- Nucletron
- Siemens Healthineers
- Theradaptive, Inc.
- Intersect ENT
- Nanomedical Systems, Inc.
- Intarcia Therapeutics
- Teleflex Incorporated
- Terumo Corporation
- Alimera Sciences
- Eyepoint Pharmaceuticals
- Delpor Inc.
- 3M Company